In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice
In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice
复制标题
DOI:
10.1523/jneurosci.0996-15.2015
复制
发表时间:
2015-11-25
影响因子:
5.3
通讯作者:
Lemere, Cynthia A.
中科院分区:
文献类型:
--
作者:
Liu, Bin;Le, Kevin X.;Lemere, Cynthia A.
Alzheimer's disease (AD) is the most common cause of dementia. Neuroinflammation appears to play an important role in AD pathogenesis. Ligands of the 18 kDa translocator protein (TSPO), a marker for activated microglia, have been used as positron emission tomography (PET) tracers to reflect neuroinflammation in humans and mouse models. Here, we used the novel TSPO-targeted PET tracer F-18-GE180 (flutriciclamide) to investigate differences in neuroinflammation between young and old WT and APP/PS1dE9 transgenic (Tg) mice. In vivo PET scans revealed an overt age-dependent elevation in whole-brain uptake of F-18-GE180 in bothWTand Tg mice, and a significant increase in whole-brain uptake of F-18-GE180 (peak-uptake and retention) in old Tg mice compared with young Tg mice and all WT mice. Similarly, the F-18-GE180 binding potential in hippocampus was highest to lowest in old Tg > old WT > young Tg > young WT mice using MRI coregistration. Ex vivo PET and autoradiography analysis further confirmed our in vivo PET results: enhanced uptake and specific binding (SUV75%) of F-18-GE180 in hippocampus and cortex was highest in old Tg mice followed by old WT, young Tg, and finally youngWTmice. F-18-GE180 specificity was confirmed by an in vivo cold tracer competition study. Wealso examined F-18-GE180 metabolites in 4-month-oldWTmice and found that, although total radioactivity declined over 2 h, of the remaining radioactivity, similar to 90% was due to parent F-18-GE180. In conclusion, F-18-GE180 PET scans may be useful for longitudinal monitoring of neuroinflammation during AD progression and treatment.